The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab, with a verdict due in the middle of next year. If approved by the 10th June action date, clesrovimab ...
Medpage Today on MSN5mon
Novel Monoclonal Antibody Protects Infants Against RSVThe investigational monoclonal antibody clesrovimab protected against respiratory syncytial virus (RSV) disease and prevented ...
New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting ...
Hosted on MSN3mon
Merck's BLA for RSV Antibody Clesrovimab Gets FDA AcceptanceIf approved, clesrovimab can help address the burden of RSV disease in time for the 2025-26 RSV season. Year to date, shares of Merck have declined 8.3% against the industry’s rise of 5.3% ...
Upcoming market catalysts for the second quarter of 2025 include the US approval decisions for clesrovimab (MK-1654) for respiratory syncytial virus (RSV) prophylaxis, sebetralstat for hereditary ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback